Skip to main content Accessibility help
×
Home

Oxypertine in Tardive Dyskinesia: An 8-week Controlled Study

  • S. D. Soni (a1), H. L. Freeman (a2) and E. M. Hussein (a3)

Summary

In a double-blind placebo controlled trial of oxypertine in the treatment of tardive dyskinesia, 33 patients with chronic schizophrenia received either oxypertine or placebo. At the end of eight weeks, the results showed that oxypertine was superior to placebo at a statistically significant level.

Copyright

References

Hide All
Bandtup, E. (1961) Tetrabenazine treatment in persisting dyskinesia caused by psychopharmacea. American Journal of Psychiatry, 118, 551–2.
Chien, C-P, Jurg, K. & Ross-Townsend, A. (1978) Efficacies of agents related to GABA, dopamine and acetylcholine in the treatment of tardive dyskinesia. Psychopharmacology Bulletin, 14, 2022.
Eckmann, F. (1968) The problems of lasting damage following long-term neuroleptic treatment. Therapie Gegeru, 107, 316–23.
Freeman, H. L., Soni, S. D. & Carpenter, L. (1980) A controlled trial of oxypertine in tardive dyskinesia. International Pharmacopsychiatry, 15, 281–91.
Kazamatsuri, H. (1980) Treatment of tardive dyskinesia with oxypertine. Comprehensive Psychiatry, 21, 352–7.
Villeneuve, A., Borszotmenyi, Z., Descharmbault, M. & Lachence, R. (1970) An attempt to treat postneuroleptic dyskinesia of the permanent type. Laval Médecin, 40, 832–7.

Oxypertine in Tardive Dyskinesia: An 8-week Controlled Study

  • S. D. Soni (a1), H. L. Freeman (a2) and E. M. Hussein (a3)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Oxypertine in Tardive Dyskinesia: An 8-week Controlled Study

  • S. D. Soni (a1), H. L. Freeman (a2) and E. M. Hussein (a3)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *